Protective potential of 17β-estradiol against co-exposure of 4-hydroxynonenal and 6-hydroxydopamine in PC12 cells

Abstract

4-hydroxynonenal (4-HNE) and 6-hydroxydopamine (6-OHDA)-mediated damage in dopaminergic neurons is well documented. Protective potential of steroidal hormone (17β-estradiol) has also been suggested. However, therapeutic potential of such promising hormone is hampered due to complex brain anatomy and physiology. Thus, the present investigations were studied to suggest the applicability of dopamine expressing PC12 cells as in vitro tool to screen the pharmacological potential of 17β-estradiol against 4-HNE and 6-OHDA. MTT assay was conducted for cytotoxicity assessment of both 4-HNE (1 μM to 50 μM) and 6-OHDA (10^-4 to 10^-7 M). Non-cytotoxic concentrations, that is, 4-HNE (1 μM) and 6-OHDA (10^-6 M) were selected to study the synergetic/additive responses. PC12 cells were found to be more vulnerable towards co-exposure of individual exposure of 4-HNE and 6-OHDA, even at non-cytotoxic concentrations. Then, cells were subjected to pre-treatment (24 hours) of 17β-estradiol (1 μM), followed by a permutation of combinations of both 4-HNE and 6-OHDA. Pretreatment of 17β-estradiol was found to be significantly effective against the cytotoxic responses of 4-HNE and 6-OHDA, when the damage was at lower level. However, 17β-estradiol was found to be ineffective against higher concentrations. Physiological-specific responses of PC12 cells against 4-HNE/6-OHDA and 17β-estradiol suggest its applicability as first tier of screening tool.

Keywords

PC12 cells 4-HNE 6-OHDA 17β-estradiol cytotoxicity

References

Adibhatla RM , Hatcher JF Lipid oxidation and peroxidation in CNS Health and disease: from molecular mechanisms to therapeutic opportunities. Antiox Redox Signal 2010; 12: 125-169.

Dmitriev LF The involvement of lipid radical cycles and the adenine nucleotide translocator in neurodegenerative diseases. J Alzheimer’s Dis 2007; 11: 183-190.

Liang LP , Huang J. , Fulton R. , Day BJ , and Patel M. An orally active catalytic metalloporphyrin protects against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine neurotoxicity in vivo. J Neurosci 2007; 27: 4326-4333.

Piga R. , Saito Y. , Yoshida Y. , and Niki E. Cytotoxic effects of various stressors on PC12 cells: involvement of oxidative stress and effect of antioxidants. Neurotoxicology 2007; 28: 67-75.

Arakawa M. , Ishimura A. , Arai Y. , Kawabe K. , Suzuki S. , Ishige K. , et al. N-Acetylcysteine and ebselen but not nifedipine protected cerebellar granule neurons against 4-hydroxynonenal-induced neuronal death. Neurosci Res 2007; 57: 220-229.

Abdul HM , Butterfield DA Involvement of PI3K/PKG/ ERK1/2 signaling pathways in cortical neurons to trigger protection by co-treatment of acetyl-L-carnitine and alpha-lipoic acid against HNE-mediated oxidative stress and neurotoxicity: implications for Alzheimer’s disease. Free Radic Biol Med 2007; 42: 371-384.

Siddiqui MA , Singh G. , Kashyap MP , Khanna VK , Yadav S. , Chandra D. , et al. Influence of cytotoxic doses of 4-hydroxynonenal on selected neurotransmitter receptors in PC-12 cells. Toxicol In Vitro 2008; 22: 1681-1688.

Mazzio EA , Reams RR , and Soliman KF The role of oxidative stress, impaired glycolysis and mitochondrial respiratory redox failure in the cytotoxic effects of 6-hydroxydopamine in vitro. Brain Res 2004; 1004: 29-44.

Inden M. , Kitamura Y. , Kondo J. , Hayashi K. , Yanagida T. , Takata K. , et al. Serofendic acid prevents 6-hydroxydopamine-induced nigral neurodegeneration and drug-induced rotational asymmetry in hemiparkinsonian rats. J Neurochem 2005; 95: 950-961.

10.

Blum D. , Torch S. , Lambeng N. , Nissou M. , Benabid AL , Sadoul R. , et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson’s disease. Prog Neurobiol 2001; 65: 135-172.

11.

Hanrott K. , Gudmunsen L. , O’Neill MJ , and Wonnacott S. 6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase C delta. J Biol Chem 2006; 281: 5373-5382.

12.

Wang T. , Zhang QJ , Liu J. , Wu ZH , and Wang S. Firing activity of locus coeruleus noradrenergic neurons increases in a rodent model of Parkinsonism. Neurosci Bull 2009; 25: 15-20.

13.

Kulkarni J. , de Castella A. , Fitzgerald PB , Gurvich CT , Bailey M. , Bartholomeusz C. , et al. Estrogen in severe mental illness: a potential new treatment approach. Arch Gen Psychiatry 2008; 65: 955-960.

14.

Bagger YZ , Tanko LB , Alexandersen P. , Qin G. , and Christiansen C. Early postmenopausal hormone therapy may prevent cognitive impairment later in life. Menopause 2005; 12: 12-17.

15.

McClean J. , Nuñez JL 17alpha-Estradiol is neuroprotective in male and female rats in a model of early brain injury. Exp Neurol 2008; 210: 41-50.

16.

Huppmann S. , Römer S. , Altmann R. , Obladen M. , and Berns M. 17beta-estradiol attenuates hyperoxiainduced apoptosis in mouse C8-D1A cell line. J Neurosci Res 2008; 86: 3420-3426.

17.

Morissette M. , Di Paolo T. Effect of estradiol on striatal dopamine activity of female hemiparkinsonian monkeys. J Neurosci Res 2008; 87: 1634-1644.

18.

Cheng MY , Sun G. , Jin M. , Zhao H. , Steinberg GK , and Sapolsky RM Blocking glucocorticoid and enhancing estrogenic genomic signaling protects against cerebral ischemia. J Cereb Blood Flow Metab 2009; 29: 130-136.

19.

Wise PM , Dubal DB , Wilson ME , Rau SW , Böttner M. , and Rosewell KL Estradiol is a protective factor in the adult and aging brain: understanding of mechanisms derived from in vivo and in vitro studies. Brain Res Brain Res Rev 2001; 37: 313-319.

20.

Wang X. , Dykens JA , Perez E. , Liu R. , Yang S. , Covey DF , et al. Neuroprotective effects of 17beta-estradiol and nonfeminizing estrogens against H2O2 toxicity in human neuroblastoma SK-N-SH cells. Mol Pharmacol 2006; 70: 395-404.

21.

Saengsirisuwan V. , Pongseeda S. , Prasannarong M. , Vichaiwong K. , and Toskulkao C. Modulation of insulin resistance in ovariectomized rats by endurance exercise training and estrogen replacement. Metabolism 2009; 58: 38-47.

22.

Zhang H. , Xie M. , Schools GP , Feustel PF , Wang W. , Lei T. , et al. Tamoxifen mediated estrogen receptor activation protects against early impairment of hippocampal neuron excitability in an oxygen/glucose deprivation brain slice ischemia model. Brain Res 2009 ; 1247:196-211.

23.

Zhao Y. , Hu I. , and Jin W. Transformation of oxidation products and reduction of estrogenic activity of 17beta-estradiol by a heterogeneous photo-Fenton reaction. Environ Sci Technol 2008; 42: 5277-5284.

24.

Hruska Z. , Dohanich GP The effects of chronic estradiol treatment on working memory deficits induced by combined infusion of beta-amyloid (1-42) and ibotenic acid. Horm Behav 2007; 52: 297-306.

25.

Perrella J. , Bhavnani BR Protection of cortical cells by equine estrogens against glutamate-induced excitotoxicity is mediated through a calcium independent mechanism. BMC Neurosci 2005; 6: 34.

26.

Wang J. , Green PS , and Simpkins JW Estradiol protects against ATP depletion, mitochondrial membrane potential decline and the generation of reactive oxygen species induced by 3-nitroproprionic acid in SK-N-SH human neuroblastoma cells. J Neurochem 2001; 77: 804-811.

27.

Regan RF , Guo Y. Estrogens attenuate neuronal injury due to hemoglobin, chemical hypoxia, and excitatory amino acids in murine cortical cultures. Brain Res 1997; 764: 133-140.

28.

Zhang P. , Li HF , Tian ZF , Qiu XQ , Wu JX , and Jia ZJ Effects of phytoestrogens and 17beta-estradiol on vasoconstriction elicited by reactive oxygen species. Pharmazie 2007 ; 62: 378-381.

29.

Galbiati F. , Volonte D. , Gil O. , Zanazzi G. , Salzer JL , Sargiacomo M. , et al. Expression of caveolin-1 and -2 in differentiating PC12 cells and dorsal root ganglion neurons: caveolin-2 is up-regulated in response to cell injury. Proc Natl Acad Sci U S A 1998; 95: 10257- 10262.

30.

Pant AB , Agarwal AK , Sharma VP , and Seth PK In vitro cytotoxicity evaluation of plastic biomedical devices. Hum Exp Toxicol 2001; 20: 412-417.

31.

Li D. , Hinshelwood A. , Gardner R. , McGarvie G. , and Ellis EM Mouse aldo-keto reductase AKR7A5 protects V79 cells against 4-hydroxynonenal-induced apoptosis. Toxicology 2006; 226: 172-180.

32.

Borovic S. , Cipak A. , Meinitzer A. , Kejla Z. , Perovic D. , Waeg G. , et al. Differential sensitivity to 4-hydroxynonenal for normal and malignant mesenchymal cells. Redox Rep 2007 ; 12: 50-54.

33.

Shi Q. , Vaillancourt F. , Cote V. , Fahmi H. , Lavigne P. , Afif H. , et al. Alterations of metabolic activity in human osteoarthritic osteoblasts by lipid peroxidation end product 4-hydroxynonenal. Arthritis Res Ther 2006; 8: 159.

34.

Chung FL , Pan J. , Choudhury S. , Roy R. , Hu W. , and Tang MS Formation of trans-4-hydroxy-2-nonenaland other enal-derived cyclic DNA adducts from omega-3 and omega-6 polyunsaturated fatty acids and their roles in DNA repair and human p53 gene mutation. Mutat Res 2005; 531: 25-36.

35.

Siddiqui MA , Singh G. , Khanna VK , Kashyap MP , Yadav S. , Chandra D. , et al. Oxidative stress mediated cellular responses in 4-hydoxynonenal exposed PC12 cells. J Ecophysiol Occup Health 2007; 7: 97-109.

36.

VChoudhary S. , Xiao T. , Srivastava S. , Zhang W. , Chan LL , Vergara LA , et al. Toxicity and detoxification of lipid-derived aldehydes in cultured retinal pigmented epithelial cells. Toxicol Appl Pharmacol 2005; 204: 122-134.

37.

Dwivedi S. , Sharma A. , Patrick B. , Sharma R. , and Awasthi YC Role of 4-hydroxynonenal and its metabolites in signaling. Redox Rep 2007; 12: 4-10.

38.

Srivastava S. , Dixit BL , Cai J. , Sharma S. , Hurst HE , Bhatnagar A. , et al. Metabolism of lipid peroxidation product, 4-hydroxynonenal (HNE) in rat erythrocytes: role of aldose reductase. Free Radic Biol Med 2000; 29: 642-651.

39.

Seth K. , Agrawal AK , Aziz MH , Ahmad A. , Shukla Y. , Mathur N. , et al. Induced expression of early response genes/oxidative injury in rat pheochromocytoma (PC12) cell line by 6-hydroxydopamine: implication for Parkinson’s disease. Neurosci Lett 2002; 330: 89-93.

40.

Bové J. , Prou D. , Perier C. , and Przedborski S. Toxin-induced models of Parkinson’s disease. NeuroRx 2005 ; 2: 484-494.

41.

Chaturvedi RK , Shukla S. , Seth K. , Chauhan S. , Sinha C. , Shukla Y. , et al. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopaminelesioned rat model of Parkinson’s disease. Neurobiol Dis 2006; 22: 421-434.

42.

Eminel S. , Klettne A. , Roemer L. , Herdegen T. , and Waetzig V. JNK2 translocates to the mitochondria and mediates cytochrome c release in PC12 cells in response to 6-hydroxydopamine. J Biol Chem 2004; 279: 55385-55392.

43.

Finkelstein EI , Ruben J. , Koot CW , Hristova M. , and van der Vliet A. Regulation of constitutive neutrophil apoptosis by the alpha,beta-unsaturated aldehydes acrolein and 4-hydroxynonenal. Am J Physiol Lung Cell Mol Physiol 2005; 289: 1019-1028.

44.

Duarte AI , Santos MS , Oliveira CR , and Rego AC Insulin neuroprotection against oxidative stress in cortical neurons-involvement of uric acid and glutathione antioxidant defenses. Free Radic Biol Med 2005; 39: 876-889.

45.

Mattson MP , Robinson N. , and Guo Q. Estrogens stabilize mitochondrial function and protect neural cells against the pro-apoptotic action of mutant presenilin-1. Neuroreport 1997; 8: 3817-3821.

46.

Carmen D. , Lobatón LV , Hernández-SanMiguel E. , SantoDomingo J. , Moreno A. , Montero M. , et al. Modulation of mitochondrial Ca2+ uptake by estrogen receptor agonists and antagonists. Br J Pharmacol 2005 ; 145: 862-871.

47.

Razmara A. , Duckles SP , Krause DN , and Procaccio V. Estrogen suppresses brain mitochondrial oxidative stress in female and male rats. Brain Res 2007; 1176: 71-81.

48.

Nilsen J. , Diaz BR Mechanism of estrogen-mediated neuroprotection: regulation of mitochondrial calcium and Bcl-2 expression. Proc Natl Acad Sci U S A 2003; 100: 2482-2487.

49.

Burris TP , Krishnan V. Estrogen: a mitochondrial energizer that keeps on going. Mol Pharmacol 2005; 68: 956-958.

50.

Stirone C. , Duckles SP , Krause DN , and Procaccio V. Estrogen increases mitochondrial efficiency and reduces oxidative stress in cerebral blood vessels. Mol Pharmacol 2005 ; 68: 959-965.